Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
FDMT 
4D Molecular Therapeutics Inc (FDMT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: FDMT (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $33.11
1 Year Target Price $33.11
| 5 | Strong Buy |
| 4 | Buy |
| 2 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 28.04% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 417.09M USD | Price to earnings Ratio - | 1Y Target Price 33.11 |
Price to earnings Ratio - | 1Y Target Price 33.11 | ||
Volume (30-day avg) 12 | Beta 2.98 | 52 Weeks Range 2.23 - 12.34 | Updated Date 01/9/2026 |
52 Weeks Range 2.23 - 12.34 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.75 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -65538.89% |
Management Effectiveness
Return on Assets (TTM) -27.64% | Return on Equity (TTM) -45.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 134286047 | Price to Sales(TTM) 3475.72 |
Enterprise Value 134286047 | Price to Sales(TTM) 3475.72 | ||
Enterprise Value to Revenue 1119.05 | Enterprise Value to EBITDA -3.55 | Shares Outstanding 57135075 | Shares Floating 42910727 |
Shares Outstanding 57135075 | Shares Floating 42910727 | ||
Percent Insiders 3.23 | Percent Institutions 72.03 |
Upturn AI SWOT
4D Molecular Therapeutics Inc
Company Overview
History and Background
4D Molecular Therapeutics (4DMT) was founded in 2013. It is a clinical-stage biotherapeutics company focused on developing gene therapies for a range of genetic diseases. The company has made significant progress in developing its proprietary AAV platform, which aims to deliver therapeutic payloads to specific tissues and cell types more effectively and safely. Key milestones include advancements in its clinical pipeline and strategic partnerships.
Core Business Areas
- Gene Therapy Development: 4DMT focuses on developing gene therapies for genetic disorders using its proprietary AAV-based platform, comprising three distinct platforms: "4D-150" for ophthalmology, "4D-125" for neuromuscular diseases, and "4D-310" for cystic fibrosis and other pulmonary diseases.
Leadership and Structure
4D Molecular Therapeutics is led by a management team with expertise in gene therapy, biotechnology, and drug development. The company operates as a typical biotechnology firm with research and development, clinical operations, manufacturing, and corporate functions.
Top Products and Market Share
Key Offerings
- 4D-150: A gene therapy candidate for inherited retinal diseases, targeting specific cell types in the eye. Market share data is not applicable as it is in clinical development. Competitors include gene therapy companies with ophthalmology programs.
- 4D-125: A gene therapy candidate for Duchenne muscular dystrophy (DMD) and other neuromuscular conditions. Market share data is not applicable as it is in clinical development. Competitors include gene therapy companies and other DMD treatment developers.
- 4D-310: A gene therapy candidate for cystic fibrosis (CF) and other pulmonary diseases. Market share data is not applicable as it is in clinical development. Competitors include companies developing CF treatments, including gene therapy approaches.
Market Dynamics
Industry Overview
The gene therapy market is a rapidly growing and innovative sector of the biopharmaceutical industry. It focuses on developing treatments for rare genetic diseases and other conditions by modifying a patient's genes. The industry is characterized by high R&D investment, complex regulatory pathways, and significant therapeutic potential.
Positioning
4D Molecular Therapeutics is positioned as a clinical-stage gene therapy company with a focus on developing best-in-class therapies through its differentiated AAV platform technology. Its competitive advantages lie in its targeted delivery capabilities and potential for improved safety and efficacy.
Total Addressable Market (TAM)
The TAM for gene therapies is substantial and growing, driven by the unmet medical needs in genetic diseases. For specific indications like Duchenne muscular dystrophy and cystic fibrosis, the TAM is in the billions of dollars globally. 4DMT is positioned to address a portion of this TAM with its pipeline programs.
Upturn SWOT Analysis
Strengths
- Proprietary AAV platform technology with potential for tissue-specific targeting and improved safety.
- Diversified pipeline targeting multiple rare genetic diseases.
- Experienced management team with expertise in gene therapy.
- Progress in clinical trials for key programs.
Weaknesses
- As a clinical-stage company, 4DMT has no approved products and faces significant development and regulatory risks.
- High cost of gene therapy development and manufacturing.
- Reliance on partnerships for certain aspects of development or commercialization.
- Potential for manufacturing scalability challenges.
Opportunities
- Advancements in gene editing and delivery technologies.
- Increasing understanding of genetic diseases and their underlying mechanisms.
- Growing market for orphan drugs and rare disease treatments.
- Potential for strategic collaborations and partnerships.
Threats
- Clinical trial failures or unexpected safety issues.
- Intense competition from other gene therapy developers.
- Evolving regulatory landscape for gene therapies.
- Reimbursement challenges for high-cost therapies.
- Intellectual property disputes.
Competitors and Market Share
Key Competitors
- Sarepta Therapeutics (SRPT)
- Pfizer Inc. (PFE)
- Roche Holding AG (RHHBY)
- Biogen Inc. (BIIB)
- Spark Therapeutics (acquired by Roche)
Competitive Landscape
4DMT competes in the highly dynamic gene therapy space. Its advantages lie in its novel AAV vector platform offering potential for improved targeting and safety. However, it faces established players with approved therapies and significant R&D budgets. Differentiated efficacy and safety profiles will be crucial for market penetration.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for 4D Molecular Therapeutics has been characterized by pipeline progression, development of its platform technology, and successful fundraising rounds to support its R&D efforts.
Future Projections: Future projections are contingent on the success of its clinical trials and potential regulatory approvals. Analyst estimates would focus on the potential market penetration and revenue generation of its lead candidates upon commercialization.
Recent Initiatives: Recent initiatives likely include advancements in ongoing clinical trials for its lead programs (4D-150, 4D-125, 4D-310), potential expansion of its preclinical pipeline, and strategic collaborations or partnerships to further develop or commercialize its technologies.
Summary
4D Molecular Therapeutics is a promising clinical-stage gene therapy company with a proprietary platform. Its strength lies in its innovative technology and diversified pipeline targeting significant unmet medical needs. However, it faces the inherent risks of clinical development, competition, and high costs. Continued successful clinical trial execution and strategic partnerships are crucial for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Websites
- SEC Filings (10-K, 10-Q)
- Industry Analysis Reports
- Financial News Outlets
Disclaimers:
This JSON output is an analysis based on publicly available information and is for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 4D Molecular Therapeutics Inc
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2020-12-11 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 227 | |
Full time employees 227 | |||
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in EmeryVille, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.